Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded at StockNews.com

StockNews.com upgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a sell rating to a hold rating in a research note published on Wednesday.

Brainstorm Cell Therapeutics Stock Down 4.7 %

BCLI stock opened at $1.82 on Wednesday. The stock has a 50-day simple moving average of $1.96 and a two-hundred day simple moving average of $2.92. Brainstorm Cell Therapeutics has a twelve month low of $1.05 and a twelve month high of $11.89. The firm has a market capitalization of $10.37 million, a PE ratio of -0.38 and a beta of 0.29.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.